Recombinant human wnt3a 5036 wn 010

Manufactured by R&D Systems

Recombinant human Wnt3A (5036-WN-010) is a purified recombinant protein produced in Human Embryonic Kidney cells (HEK293). It has a molecular weight of approximately 39 kDa. The protein is presented as a lyophilized powder.

Automatically generated - may contain errors

Lab products found in correlation

17β estradiol e2, by Merck Group (1 mentions) T 5224, by Cayman Chemical (1 mentions) Lgk974, by Cayman Chemical (1 mentions) Marimastat, by Selleck Chemicals (1 mentions) Fulvestrant, by Merck Group (1 mentions) Ethylene diamine tetraacetic acid (edta), by Bio-Techne (1 mentions) Q5 site directed mutagenesis kit, by New England Biolabs (1 mentions) Trametinib t 8123, by LC Laboratories (1 mentions)

Close spelling variants of this product

Wnt3a (251 citations) Recombinant human Wnt3a (73 citations) Recombinant Wnt3a (56 citations) Human Wnt3A (7 citations) Recombinant human Wnt3A (#5036-WN, (3 citations) Wnt3a (5036-WN) (3 citations) Wnt3a (5036-WN-010) (2 citations)

2 protocols using recombinant human wnt3a 5036 wn 010

Reagents and Knockdown Methods for Wnt3A Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

17β-estradiol (E2, #E8875) was obtained from Sigma, and Fulvestrant (#1047), carbenoxolone disodium (#3096) and EDTA (#2811) were purchased from Tocris. LGK974 (#14072) and T-5224 (#22904) were purchased from Cayman. Marimastat (S7156) was obtained from SelleckChem. Recombinant human Wnt3A (5036-WN-010) was purchased from R&D Systems. For knockdown experiments, siRNA against FOXA1 (#M-010319), DSC1 (#L-011995), DSC2 (#L-011996), GJA1 (#L-011042) and GJB2 (#L-019285) were obtained from Horizon Discovery. Desmosome and scramble peptides were designed based on previous studies (21 ,22 (link)) and synthesized from GeneScript. Peptide sequences are presented in Supplementary Table S10.

Li Z., Wu Y., Yates M.E., Tasdemir N., Bahreini A., Chen J., Levine K.M., Priedigkeit N.M., Nasrazadani A., Ali S., Buluwela L., Arnesen S., Gertz J., Richer J.K., Troness B., El-Ashry D., Zhang Q., Gerratana L., Zhang Y., Cristofanilli M., Montanez M.A., Sundd P., Wallace C.T., Watkins S.C., Fumagalli C., Guerini-Rocco E., Zhu L., Tseng G.C., Wagle N., Carroll J.S., Jank P., Denkert C., Karsten M.M., Blohmer J.U., Park B.H., Lucas P.C., Atkinson J.M., Lee A.V, & Oesterreich S. (2022). Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer research, 82(7), 1321-1339.

+ Open protocol

+ Expand

Modulating Wnt3a Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

HA-KDM4A, HA-KDM4B, HA-KDM4C, and Myc-TCF4 plasmids were from Addgene. Lentivirus pLenti-GIII-CMV-human-WNT3A-HA lentiviral vector (CMV-hWNT3A-HA; LV358590) was from ABM. Flag-β-TrCP, Myc-ubiquitin, and HA-ubiquitin plasmids were a gift from Dr. Yue Xiong (University of North Carolina, Chapel Hill, NC). Flag-KDM4C and Flag-TCF4 were subcloned into p3×Flag-23 (Sigma-Aldrich). HA-KDM4C mutants S713A-, S918A-, D914A-, D914A/S918A-, H190A/E192A-, and shRNA-resistant mutants, were constructed using a Q5 site-directed mutagenesis kit (E0554) from NEB. Recombinant human Wnt3a (5036-WN-010) and recombinant human DKK1 (5493-DK-010) were from R&D Systems. The kinase inhibitors SB203580 (S-3400), SP600125 (S-7979), and Trametinib (T-8123) were purchased from LC Laboratories. pGIPZ lentivirus shKDM4C plasmids (RHS4531-EG23081) and SMARTpool siGENOME KDM4C siRNA (M-004293-02-0005) were purchased from GE Dharmacon. Other siRNAs were synthesized by Sigma, and the sequences are listed in Supplementary Table 1.

Chen Y., Fang R., Yue C., Chang G., Li P., Guo Q., Wang J., Zhou A., Zhang S., Fuller G.N., Shi X, & Huang S. (2019). Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis. Cancer research, 80(5), 1049-1063.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!